The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Reading Rheum

Reading Rheum

June 1, 2007 • By Daniel Hal Solomon, MD, MPH; Michael M. Ward, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

TNF Agonists and Mortality

By Daniel Hal Solomon, MD, MPH
Carmona L, Descalzo MA, Pérez-Pampín E, et al. All cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with TNF antagonists. Ann Rheum Dis. Online before print. February 26, 2007. doi:10.1136/ard.2006.067660.

You Might Also Like
  • Reading RHEUM
  • Reading Rheum
  • Reading Rheum
Explore This Issue
June 2007

Abstract

Background: Mortality is increased in RA mainly due to cardiovascular events, cancer, and infections. Recent data suggest that treatment with tumor necrosis factor (TNF) antagonists may affect this trend.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Objective: To assess whether treatment with TNF antagonists is associated with reduction in cardiovascular events, cancer and infection rates, and in mortality in RA patients treated compared with those not treated with TNF antagonists.

Methods: BIOBADASER is a registry for active long-term follow-up of safety of biological therapies in rheumatic patients. It includes 4,459 RA patients treated with TNF antagonists. EMECAR is an external RA cohort (n=789) established to define the characteristics of the disease in Spain and to assess comorbidity. The incidence density (IHD) of cardiovascular events, cancer, and infections was estimated and compared in both cohorts. The Standardized Mortality Ratio (SMR) was compared with the rate in the general population. A propensity score was used to match cohorts by the probability of being treated.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Results: Rates of cardiovascular and cancer events are significantly higher in EMECAR than in BIOBADASER (Rate ratio [RR]=5 to 7 for different cardiovascular events, and RR=2.9 for cancer), whereas rate of serious infections is significantly higher in BIOBADASER (RR=1.6). Mortality-rate ratio of BIOBADASER by EMECAR is 0.32 (0.20–0.53) for all causes of death, 0.58 (0.24–1.41) for cardiovascular, 0.52 (0.21–1.29) for infection, and 0.36 (0.10–1.30) for cancer-related deaths.

Conclusion: Morbidity (other than infection) and mortality are not higher than expected in patients with RA treated with TNF antagonist.

Commentary

BIOBADASER and EMECAR researchers investigate a topic of great concern: whether TNF antagonists are associated with excess mortality in patients with RA. Because trials of TNF antagonists are relatively small and short in duration, this question will best be answered by careful epidemiologic studies. To this end, the current analyses compare all-cause and cause-specific mortality among patients with RA treated with and without a TNF antagonist. While we should probably accept the conclusion that there is no greater mortality risk among TNF-antagonist users, the assertion that all-cause mortality may actually be reduced in this group warrants careful inspection.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

These investigators have systematically collected data on outcomes in two national registries of RA. BIOBADASER has enrolled TNF-antagonist users and EMECAR synthetic–disease-modifying antirheumatic drug (DMARD) users. Information collected in these two registries is similar but not identical, and many of the same clinical centers participate in both registries. The difficult methodological issue for this analysis is ensuring the comparability of the study groups. While this goal sounds simple, it turns out to be quite difficult even for established epidemiologists. It may even be more difficult in countries where regulators restrict use of expensive TNF antagonists to certain types of patients, almost ensuring that the two groups will not be comparable. These restrictions usually focus on RA disease activity measures. However, even more problematic than non-overlap in RA disease activity is the possibility of different distributions of comorbid conditions. Patients with severe RA who are not prescribed a TNF antagonist often have comorbidities that make clinicians and patients cautious about using an infusion or injectable medication with an incompletely understood side-effect profile.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Research Reviews, Rheumatoid Arthritis Tagged With: mortality, patient care, Reading Rheum, Research, Rheumatoid Arthritis (RA), TNF antagonist, TreatmentIssue: June 2007

You Might Also Like:
  • Reading RHEUM
  • Reading Rheum
  • Reading Rheum
  • Reading Rheum

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)